Milestone Pharmaceuticals Inc. (MIST): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 07:36 ET
- Event date
- 2026-11-13
- Accession no.
- 0001104659-26-126519
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Milestone reports third-quarter results and plans approximately 30% operating expense reduction
Milestone reported third-quarter product revenue of $1.0 million and a net loss of $25.8 million. It announced measures expected to reduce operating expenses by approximately 30% and expects cash runway into late 2028. The AFib-RVR Phase 3 trial remains on schedule, with topline data expected in the second half of 2028.
- Cash, cash equivalents, and short-term investments totaled $145.4 million as of September 30, 2026.
- Cost-efficiency measures include headquarters workforce reductions and approximately $2 million in expected one-time charges.
- CFO Amit Hasija and CMO David Bharucha departed the leadership team; Anthony Krick was named Principal Financial and Principal Accounting Officer.
- The RTW note agreement amendment extends payment-in-kind interest from March 31, 2027 to March 2029.
earningsrestructuringguidance
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | FORM 8-K | tm2629645d1_8k.htm |
| EX-99.1 | EXHIBIT 99.1 | tm2629645d1_ex99-1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.